This healthcare stock which is a leading manufacturer and exporter of medical devices, specializing in products for oncology, infusion therapy, cardiology, and various other healthcare applications, skyrocketed 11.66 percent it reported its quarterly result and announced revenue guidance of more than 20 percent revenue growth over the next 2 to 3 years.
Stock Price Movement
In Tuesday’s trading session, Poly Medicure Limited’s share jumped to an intraday high of 11.66 percent from the previous close of Rs. 2,283.65. The stock opened at Rs. 2,295.95 and is currently trading at Rs. 2,266.25, with a high of Rs. 2,550 and a low of Rs. 2,266.25. The market capitalization now stands at approximately Rs. 25,376.01 crore.
What is the news?
Himanshu Baid, Managing Director of Poly Medicure Limited, shared the company’s guidance for the upcoming years during an interview on CNBC TV18. He stated that the company is targeting more than 20 percent revenue growth over the next 2 to 3 years. Additionally, the company expects its margins to improve by 100–120 basis points on a full-year basis.
For FY 2025, Poly Medicure expects revenue growth in the range of 22 percent to 24 percent. He highlighted that the company’s domestic revenue is projected to grow by 20 percent, while export revenue is expected to rise by 26 percent. The contribution from domestic sales will be 70 percent, while export revenue will make up 30 percent.
Additionally, he also mentioned that the European market is anticipated to grow by 30-35 percent over the next two years. Regarding the US market, Poly Medicure aims to generate $3 million in revenue for FY 2025, through the sales of four out of five products. Additionally, the company expects its margins to improve by 100–120 basis points on a full-year basis.
Also read….
Q3 FY25 Result Walkthrough
Coming into the quarterly results of Poly Medicure Limited, the company’s consolidated revenue from operations increased by 24.91 percent YOY, from Rs. 339.60 crore in Q3 FY24 to Rs. 424.21 crore in Q3 FY25, and grew slightly by 1 percent QoQ from Rs. 420.02 crore in Q2 FY25.
Further, the company’s EBIDT has increased by 26.2 percent, from Rs. 90.3 crore in Q3 FY24 to Rs. 114 crore in Q3 FY25.
In Q3 FY25, Poly Medicure Limited’s consolidated net profit increased by 31.08 percent YOY, reaching Rs. 85.23 crore compared to Rs. 65.02 crore during the same period last year. As compared to Q2 FY25, the net profit has decreased by 2.60 percent, from Rs. 87.45 crore.
The basic earnings per share increased by 25.07 percent and stood at Rs 8.48 as against Rs 6.78 recorded in the same quarter in the previous year 2024.
Business Operation
Poly Medicure is a leading player in the medical device industry, with 12 manufacturing plants across four countries and a presence in over 125 countries. The company produces more than 1,200 medical devices and holds 334 patents, reflecting its strong commitment to innovation.
With a workforce of over 3,000 employees, Polymed has an annual production capacity of 1.7 billion devices. Their extensive distribution network includes more than 475 sales associates and more than 600 distributors in India and 240 globally.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
